Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trial.
desmoplastic
infants
medulloblastoma
myeloablative chemotherapy
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
18 12 2020
18 12 2020
Historique:
pubmed:
19
4
2020
medline:
23
3
2021
entrez:
19
4
2020
Statut:
ppublish
Résumé
"Head Start" III, was a prospective clinical trial using intensive induction followed by myeloablative chemotherapy and autologous hematopoietic cell rescue (AuHCR) to either avoid or reduce the dose/volume of irradiation in young children with medulloblastoma. Following surgery, patients received 5 cycles of induction followed by myeloablative chemotherapy using carboplatin, thiotepa, and etoposide with AuHCR. Irradiation was reserved for children >6 years old at diagnosis or with residual tumor post-induction. Between 2003 and 2009, 92 children <10 years old with medulloblastoma were enrolled. Five-year event-free survival (EFS) and overall survival (OS) rates (±SE) were 46 ± 5% and 62 ± 5% for all patients, 61 ± 8% and 77 ± 7% for localized medulloblastoma, and 35 ± 7% and 52 ± 7% for disseminated patients. Nodular/desmoplastic (ND) medulloblastoma patients had 5-year EFS and OS (±SE) rates of 89 ± 6% and 89 ± 6% compared with 26 ± 6% and 53 ± 7% for classic and 38 ± 13% and 46 ± 14% for large-cell/anaplastic (LCA) medulloblastoma, respectively. In multivariate Cox regression analysis, histology was the only significant independent predictor of EFS after adjusting for stage, extent of resection, regimen, age, and sex (P <0.0001). Five-year irradiation-free EFS was 78 ± 8% for ND and 21 ± 5% for classic/LCA medulloblastoma patients. Myelosuppression was the most common toxicity, with 2 toxic deaths. Twenty-four survivors completed neurocognitive evaluation at a mean of 4.9 years post-diagnosis. IQ and memory scores were within average range overall, whereas processing speed and adaptive functioning were low-average. We report excellent survival and preservation of mean IQ and memory for young children with ND medulloblastoma using high-dose chemotherapy, with most patients surviving without irradiation.
Sections du résumé
BACKGROUND
"Head Start" III, was a prospective clinical trial using intensive induction followed by myeloablative chemotherapy and autologous hematopoietic cell rescue (AuHCR) to either avoid or reduce the dose/volume of irradiation in young children with medulloblastoma.
METHODS
Following surgery, patients received 5 cycles of induction followed by myeloablative chemotherapy using carboplatin, thiotepa, and etoposide with AuHCR. Irradiation was reserved for children >6 years old at diagnosis or with residual tumor post-induction.
RESULTS
Between 2003 and 2009, 92 children <10 years old with medulloblastoma were enrolled. Five-year event-free survival (EFS) and overall survival (OS) rates (±SE) were 46 ± 5% and 62 ± 5% for all patients, 61 ± 8% and 77 ± 7% for localized medulloblastoma, and 35 ± 7% and 52 ± 7% for disseminated patients. Nodular/desmoplastic (ND) medulloblastoma patients had 5-year EFS and OS (±SE) rates of 89 ± 6% and 89 ± 6% compared with 26 ± 6% and 53 ± 7% for classic and 38 ± 13% and 46 ± 14% for large-cell/anaplastic (LCA) medulloblastoma, respectively. In multivariate Cox regression analysis, histology was the only significant independent predictor of EFS after adjusting for stage, extent of resection, regimen, age, and sex (P <0.0001). Five-year irradiation-free EFS was 78 ± 8% for ND and 21 ± 5% for classic/LCA medulloblastoma patients. Myelosuppression was the most common toxicity, with 2 toxic deaths. Twenty-four survivors completed neurocognitive evaluation at a mean of 4.9 years post-diagnosis. IQ and memory scores were within average range overall, whereas processing speed and adaptive functioning were low-average.
CONCLUSION
We report excellent survival and preservation of mean IQ and memory for young children with ND medulloblastoma using high-dose chemotherapy, with most patients surviving without irradiation.
Identifiants
pubmed: 32304218
pii: 5821791
doi: 10.1093/neuonc/noaa102
pmc: PMC7746930
doi:
Substances chimiques
Carboplatin
BG3F62OND5
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1862-1872Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Cancer Cell. 2017 Jun 12;31(6):737-754.e6
pubmed: 28609654
J Clin Oncol. 2005 Oct 20;23(30):7621-31
pubmed: 16234523
J Clin Oncol. 2004 Dec 15;22(24):4881-7
pubmed: 15611503
J Child Neurol. 1995 May;10(3):209-12
pubmed: 7642890
Lancet Oncol. 2005 Aug;6(8):573-80
pubmed: 16054568
Br J Clin Psychol. 2010 Jun;49(Pt 2):235-58
pubmed: 19646334
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
Int J Dev Neurosci. 1994 Jun;12(4):327-34
pubmed: 7976487
Anticancer Drugs. 2013 Feb;24(2):189-97
pubmed: 23187460
J Neurooncol. 2011 Jan;101(2):287-95
pubmed: 20526792
N Engl J Med. 1993 Jan 14;328(2):87-94
pubmed: 8416438
J Clin Oncol. 2011 Apr 10;29(11):1408-14
pubmed: 20823417
J Clin Exp Neuropsychol. 1994 Feb;16(1):21-42
pubmed: 8150888
Pediatr Blood Cancer. 2014 Sep;61(9):1644-52; quiz 1653-72
pubmed: 24789527
Pediatr Neurol. 2015 Jul;53(1):31-46
pubmed: 26092413
J Clin Oncol. 1999 Dec;17(12):3720-8
pubmed: 10577843
Lancet Oncol. 2018 Jun;19(6):768-784
pubmed: 29778738
Acta Neuropathol. 2014 Jul;128(1):137-49
pubmed: 24791927
J Clin Oncol. 2001 Aug 1;19(15):3470-6
pubmed: 11481352
J Clin Oncol. 2006 Apr 20;24(12):1924-31
pubmed: 16567768
Eur J Cancer. 1990 Apr;26(4):492-5
pubmed: 2141516
J Clin Oncol. 1990 Jul;8(7):1277-80
pubmed: 2358840
Eur J Cancer. 2016 Jan;53:5-15
pubmed: 26687017
Radiology. 1969 Dec;93(6):1351-9
pubmed: 4983156
Pediatr Blood Cancer. 2008 Jun;50(6):1169-75
pubmed: 18293379
J Clin Oncol. 2020 Jan 20;38(3):223-231
pubmed: 31774708
Med Pediatr Oncol. 1997 May;28(5):348-54
pubmed: 9121399
Acta Neuropathol. 2012 Apr;123(4):473-84
pubmed: 22358457
Eur J Cancer. 2010 Jan;46(1):120-33
pubmed: 19818598
N Engl J Med. 2005 Mar 10;352(10):978-86
pubmed: 15758008
J Clin Oncol. 2012 Sep 10;30(26):3181-6
pubmed: 22851568
Pediatr Blood Cancer. 2010 Mar;54(3):429-36
pubmed: 20052775
Ann Oncol. 2010 Jan;21(1):19-26
pubmed: 19875758